Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

CALECIM® Cosmeceuticals Proud to Announce Mitchel P. Goldman MD as Chairman of the CALECIM® Professional Medical Advisory Board
  • USA - English


News provided by

Goldman Marketing Group

Jun 15, 2017, 06:00 ET

Share this article

Share toX

Share this article

Share toX

Prof. Mitchel P. Goldman, MD, Chairman of the CALECIM® Professional Medical Advisory Board
Prof. Mitchel P. Goldman, MD, Chairman of the CALECIM® Professional Medical Advisory Board

Singapore (PRWEB) June 15, 2017 -- Singapore bio-tech firm CellResearch Corporation, which manufactures a unique skin care line called CALECIM® Professional, is proud to work with San Diego-based and highly acclaimed skin rejuvenation expert Dr. Mitchel Goldman, who will be Chairman of the CALECIM® Professional Medical Advisory Board. This exciting relationship will allow CALECIM® Professional and Dr. Goldman (a pioneer in skin rejuvenation and research) to collaborate on a variety of projects, including clinical trials and new product development.

I’m honored to be part of CALECIM®’s medical board and look forward to our work and the exciting results that are about to unfold.

Post this

Gavin Tan, CEO of CellResearch Corporation, which owns CALECIM® Cosmeceuticals, says of the partnership: “This is exciting news for both CALECIM® and CellResearchCorp. With Dr. Goldman, we’re partnered with the ‘grandfather’ of growth factors, if you will, and our research aims to provide patients with a solution for a variety of skin concerns.”

Dr. Goldman adds, “I’m selective when I collaborate, but making the decision to affiliate with CALECIM® was a no-brainer. CALECIM® Professional is particularly exciting because of the extensive body of science behind it. This is the first time that cord lining stem cells – or stem cells in general – are being truly utilized in skincare health. Initial observations of the effects of CALECIM® on the skin have been very encouraging, and I see incredible potential. I’m honored to be part of CALECIM®’s medical board and look forward to our work and the exciting results that are about to unfold.”

As the founder of Cosmetic Laser Dermatology in San Diego, Co-Founder of SkinMedica, and author of numerous textbooks, publications, and public lectures, Dr. Goldman is considered the foremost expert in both the research and cosmetic utility of growth factors: proteins that help keep the skin healthy and firm. The skin care products created by CALECIM® Professional are considered cosmeceuticals because they have both cosmetic and therapeutic properties created with a unique combination of powerful proteins and growth factors that have multiple benefits for the skin. These powerful proteins and growth factors, derived from the culture of cord lining extract, utilize CellResearchCorp’s unique stem cell technology and are versatile enough to treat various skin concerns.

“Repairing skin elasticity and improving skin density are very difficult goals, especially for a topical application. But there has been visible evidence that CALECIM® Professional can work effectively on improving signs of aging that are hard to address, such as skin laxity and poor skin tone,” Says Mr. Tan. “Amazingly, this stem cell treatment comes from the outer lining of the umbilical cord. The umbilical cord extract is a protein-rich formula that stimulates the skin’s self-healing properties and nourishes the skin to help it look and feel younger. We are currently conducting a clinical trial using Multi-Action Cream from the CALECIM® Professional line to further research its effects on skin density, elasticity, and pigmentation.”

Dr. Goldman is conducting an Institutional Review Board approved clinical trial using CALECIM® Professional Multi-Action Cream for presentation at upcoming medical conferences and publication in peer-reviewed medical literature. In addition, this affiliation will lead to the co-development of CALECIM® technology and application in clinics, as well as the co-development of CALECIM® Professional product range, and to further global education of growth factor technology in skincare.

Dr. Goldman will be travelling to Asia in the fall of 2017 to present his findings before returning to the U.S. to present CALECIM® Professional to the American market. To learn more about the exciting partnership between CALECIM® Professional and Dr. Goldman, please visit https://calecimprofessional.com/.

“The CALECIM® Professional skin care line is backed by an extensive body of science,” Mr. Tan says. “The elasticity and tone of the skin shows noticeable improvement, not always easy for an anti-aging treatment. CALECIM® Cosmeceuticals is very excited about this partnership because it’s going to help us spread the word on the benefits of our unique stem cell derived proteins and growth factors in skin care treatment.”

CellResearch Corporation is a Singapore-based biotech company that discovered a rich and abundant source of stem cells in the umbilical cord lining in 2004. This novel and significant discovery is patent protected in 41 territories world-wide. Apart from CALECIM® Cosmeceuticals, another line of business that CellResearchCorp owns is called CordLabs, which licenses cord lining stem cell banking technology to cord blood and tissue banks. CellResearchCorp is also actively formulating a cord lining stem cell-based wound-healing drug that is currently undergoing USFDA trials for use on chronic diabetic wounds and other hard-to-heal wounds. The company uses its patents to enhance collaborations with research groups in the U.S. and around the world. This allows CellResearchCorp's proprietary stem cell technology to achieve its full potential as a platform to treat a wide-range of diseases, including those of the skin, brain, heart, and cornea.

More information on CellResearchCorp can be found at http://www.cellresearchcorp.com/.

Risa Goldman, Goldman Marketing Group, +1 818-861-7092, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.